<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00770640</url>
  </required_header>
  <id_info>
    <org_study_id>ATS K029</org_study_id>
    <secondary_id>2007-006744-21</secondary_id>
    <secondary_id>DE-PIO-029</secondary_id>
    <secondary_id>U1111-1114-1645</secondary_id>
    <nct_id>NCT00770640</nct_id>
  </id_info>
  <brief_title>Efficacy of Pioglitazone and Insulin in Treating Subjects With Type 2 Diabetes Mellitus and Renal Failure.</brief_title>
  <acronym>PIOren</acronym>
  <official_title>Comparison of the Effects of Pioglitazone vs. Placebo When Given in Addition to Standard Insulin Treatment in Patients With Type 2 Diabetes Mellitus and Renal Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the metabolic and cardiovascular effects of&#xD;
      pioglitazone, once daily (QD), and insulin combination therapy in subjects with Type 2&#xD;
      Diabetes and Renal Failure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with type 2 diabetes mellitus and clinically significant kidney disease presenting&#xD;
      with contra-indications for metformin and sulfonylurea drugs are usually treated with insulin&#xD;
      therapy only. While the prolonged pharmacokinetic insulin profile due to delayed renal&#xD;
      insulin elimination already is a hurdle for a successful therapy, impaired kidney function&#xD;
      results in increased oxidative stress and cardiovascular risk, especially in patients&#xD;
      requiring dialysis. Several potential mechanisms may explain this increased cardiovascular&#xD;
      risk, and one, frequent finding is coexistence of several other independent cardiovascular&#xD;
      risk factors including dyslipidemia, hypertension and smoking. In addition, impaired kidney&#xD;
      function is associated with elevated markers of inflammation and other putative risk factors&#xD;
      for cardiovascular events.&#xD;
&#xD;
      The focus of this study is to investigate whether pioglitazone may help improve overall&#xD;
      metabolic and cardiovascular risks in patients with end stage renal disease, and if&#xD;
      pioglitazone can potentially exert positive effects on kidney function in patients with renal&#xD;
      failure requiring dialysis.&#xD;
&#xD;
      The duration of treatment for patients completing the study is approximately 26 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of total daily Insulin Dose.</measure>
    <time_frame>Week 24 or Final Visit.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Individual insulin doses to assess the number of patients with insulin reduction of greater than or equal to 30%.</measure>
    <time_frame>Weeks 12 and 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Glycosylated Hemoglobin.</measure>
    <time_frame>Weeks 12 and 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Glucose.</measure>
    <time_frame>Weeks 12 and 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Insulin.</measure>
    <time_frame>Weeks 12 and 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in C-peptide.</measure>
    <time_frame>Weeks 12 and 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Intact Proinsulin.</measure>
    <time_frame>Weeks 12 and 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Adiponectin.</measure>
    <time_frame>Weeks 12 and 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Angiotensin.</measure>
    <time_frame>Weeks 12 and 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Relaxin.</measure>
    <time_frame>Weeks 12 and 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in fetuin A.</measure>
    <time_frame>Weeks 12 and 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Carbonyl Protein.</measure>
    <time_frame>Weeks 12 and 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Myeloperoxidase.</measure>
    <time_frame>Weeks 12 and 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Matrix-Gla Protein.</measure>
    <time_frame>Weeks 12 and 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in High Sensitivity C-reactive Protein.</measure>
    <time_frame>Weeks 12 and 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Cholesterol.</measure>
    <time_frame>Weeks 12 and 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in High-Density Lipoprotein.</measure>
    <time_frame>Weeks 12 and 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Low-Density Lipoprotein.</measure>
    <time_frame>Weeks 12 and 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Oxidized Low-Density Lipoprotein.</measure>
    <time_frame>Weeks 12 and 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Triglycerides.</measure>
    <time_frame>Weeks 12 and 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Matrix Metalloproteinase -9.</measure>
    <time_frame>Weeks 12 and 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Monocyte Chemoattractant Protein -1.</measure>
    <time_frame>Weeks 12 and 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in E-selectin.</measure>
    <time_frame>Weeks 12 and 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pioglitazone in serum.</measure>
    <time_frame>Week 12.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in intact Parathyroid Hormone.</measure>
    <time_frame>Weeks 12 and 24 or Final Visit.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Pioglitazone 30mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(and variable insulin therapy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo QD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>(and variable insulin therapy)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone and insulin</intervention_name>
    <description>Pioglitazone 30 mg, tablets, orally, once daily and variable insulin therapy for up to 24 weeks.</description>
    <arm_group_label>Pioglitazone 30mg QD</arm_group_label>
    <other_name>ACTOS®</other_name>
    <other_name>AD-4833</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Pioglitazone placebo-matching tablets, orally, once daily and variable insulin therapy for up to 24 weeks.</description>
    <arm_group_label>Placebo QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has Type 2 Diabetes Mellitus, and is a patient on insulin treatment for at least 3&#xD;
             months.&#xD;
&#xD;
          -  Has a body mass index less than 36 kg/m²&#xD;
&#xD;
          -  Has a glycosylated hemoglobin level greater than or equal to 6.0% and less than 10%.&#xD;
&#xD;
          -  Patient is on hemo-dialysis with or without residual excretion&#xD;
&#xD;
          -  An insulin dose greater than 20 IE/day&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a history of type 1 diabetes.&#xD;
&#xD;
          -  Has acute infections.&#xD;
&#xD;
          -  History of hypersensitivity to the study drugs or to drugs with similar chemical&#xD;
             structures.&#xD;
&#xD;
          -  History of severe or multiple allergies.&#xD;
&#xD;
          -  Has a progressive fatal disease other than kidney failure.&#xD;
&#xD;
          -  Has a history of drug or alcohol abuse within the last 5 years.&#xD;
&#xD;
          -  A history of significant cardiovascular (e.g. Coronary heart failure based on New York&#xD;
             Heart Association stage III - IV), respiratory, gastrointestinal, hepatic (e.g.&#xD;
             alanine aminotransferase greater than 2.5 times the normal reference range) or&#xD;
             hematological disease.&#xD;
&#xD;
          -  History of primary hyperaldosteronism&#xD;
&#xD;
          -  Acute myocardial infarction, open heart surgery or cerebral event (stroke/transient&#xD;
             ischemic attack) within the last year prior to study start.&#xD;
&#xD;
          -  Any further antidiabetic treatment except pioglitazone and insulin.&#xD;
&#xD;
          -  History of macular edema.&#xD;
&#xD;
          -  Is required to take or intends to continue taking any disallowed medication, any&#xD;
             prescription medication, herbal treatment or over-the counter medication that may&#xD;
             interfere with evaluation of the study medication, including:&#xD;
&#xD;
               -  Treatment with any other investigational drug within 3 months before trial entry.&#xD;
&#xD;
               -  Treatment with steroids within 3 months before trial entry.&#xD;
&#xD;
               -  Treatment with thiazolidinediones within the past 3 months.&#xD;
&#xD;
               -  If statin therapy applicable: Change of medication within the last 4 weeks.&#xD;
&#xD;
               -  Pre-treatment with gemfibrozil within the last 12 weeks.&#xD;
&#xD;
               -  Pre-treatment with rifampicin within the last 12 weeks.&#xD;
&#xD;
          -  Has uncontrolled unstable angina.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda Pharma GmbH, Aachen (Germany)</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Schwetzingen</city>
        <state>Baden-Württemberg</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wiesbaden</city>
        <state>Hessen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bottrop</city>
        <state>Nordrhein-Westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Düsseldorf</city>
        <state>Nordrhein-Westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lüdenscheid</city>
        <state>Nordrhein-Westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Solingen</city>
        <state>Nordrhein-Westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alzey</city>
        <state>Rheinland-Pfalz</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ingelheim</city>
        <state>Rheinland-Pfalz</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://general.takedapharm.com/content/file/pi.pdf?applicationcode=ab2d7112-8eb3-465a-8fda-35018a9eafb0&amp;fileTypeCode=ACTOSPI</url>
    <description>ACTOS® Package Insert</description>
  </link>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>October 9, 2008</study_first_submitted>
  <study_first_submitted_qc>October 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2008</study_first_posted>
  <last_update_submitted>August 31, 2010</last_update_submitted>
  <last_update_submitted_qc>August 31, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2010</last_update_posted>
  <responsible_party>
    <name_title>Medical Director</name_title>
    <organization>Takeda Pharma GmbH, Aachen (Germany)</organization>
  </responsible_party>
  <keyword>Glucose Metabolism Disorder</keyword>
  <keyword>Dysmetabolic Syndrome</keyword>
  <keyword>Type II Diabetes</keyword>
  <keyword>Diabetes Mellitus, Lipoatrophic</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

